Abstract

Inhibiting of Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) binding is an effective way for reducing Low Density Lipoprotein cholesterol (LDL-C). Understanding the interaction between PCSK9 and LDLR is useful for PCSK9 inhibitor design. In this work, MD simulations with the standard (non-polarizable) AMBER force field and effective polarizable bond (EPB) force field were performed for wild type and four mutants of PCSK9 and EGFA (Epidermal Growth Factor-like repeat A) domain of LDLR complexes. These four mutants are gain-of-function mutants. The analysis of hydrogen bond dynamics and the relative binding free energy indicates that EPB is more reliable in simulating protein dynamics and predicting relative binding affinity. Structures sampled from MD simulations with the standard AMBER force field deviate too far away from crystal structures. Many important interaction components between of PCSK9 and EGFA no longer exist in the simulation with the Amber force field. For comparison, simulation using EPB force field gives more stable structures as shown by hydrogen bond analysis and produced relative binding free energies that are consistent with experimental results. Our study suggests that inclusion of polarization effects in MD simulation is important for studying the protein-protein interaction.

Highlights

  • Cholesterol is an important substance of life

  • The interaction surface is dominated by an antiparallel β-sheet between epidermal growth factor-like repeat A (EGFA) and the exposed side of a βhairpin loop of Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) C

  • MD simulations and binding energy analysis were performed to the wild type (WT) PCSK9 CEGFA (2W2M) and GOF mutants PCSK9 CD374A-EGFA (2W2P), PCSK9 CD374Y-EGFA (2W2O), PCSK9 CD374HEGFA (2W2Q) respectively

Read more

Summary

Introduction

Cholesterol is an important substance of life. It is carried by lipoproteins to where it needs to go and functions in cell membrane, cell signaling, and nerve conduction. It is known that the low density lipoprotein (LDL) cholesterol is the “bad” cholesterol. When the concentrations of plasma LDL cholesterol (LDL-C) are too high in vivo, they gather on the walls of the blood vessels and may cause blockages. The low-density lipoprotein receptor (LDLR) is a transmembrane protein, it binds to circulating LDL, and the LDLR/LDL complex is internalized by clathrin-mediated endocytosis. At low pH in the endosomes, the LDLR/LDL complex dissociates allowing receptor recycling and lysosomal degradation of LDL. LDLR is the primary worker for removal of cholesterol from the circulation (Brown et al, 1997; Lagor and Millar, 2010). The LDLR is a 839-amino-acids protein and contains 5 domains: (1) LDLR type A repeat domains, (2) epidermal growth factor (EGF) receptor

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call